AI assistant
NEKTAR THERAPEUTICS — Director's Dealing 2018
Apr 13, 2018
32134_dirs_2018-04-12_298b0586-dcf9-4a41-81a2-5a65949ef0ca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2018-04-10
Reporting Person: Hora Maninder (SVP Pharma Dev & Mfg Ops)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-04-10 | Common Stock | M | 502 | $7.21 | Acquired | 80763 | Direct |
| 2018-04-10 | Common Stock | S | 502 | $105.67 | Disposed | 80261 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-04-10 | Stock Option | $7.21 | M | 502 | Disposed | 2020-02-07 | Common Stock (502) | Direct |
Footnotes
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This number includes 6,500 shares held by the reporting person from the Issuer's ESPP plan. The acquisition of these shares under this plan is exempt under Rule 16b-3(c).
F3: This transaction was executed in multiple trades at prices ranging from $105.03 to $105.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.